Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616586 · ClinicalTrials.gov registry record · Phase 3
SILtuximab in Viral ARds (SILVAR) Study
A Phase 3 study, sponsored by Recordati Group.
- Terminated
- Registry status
- Phase 3
- Development phase
- 555
- Enrollment target
NCT04616586 is a Phase 3 study that was terminated before completion, run by Recordati Group. The registered enrollment target is 555 participants.
The verdict
NCT04616586, a Phase 3 study, was terminated before completion, sponsored by Recordati Group.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 555 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with acute respiratory distress syndrome (ARDS) and elevated C-reactive protein (CRP) levels.
Interventions
- DRUG Siltuximab
- OTHER Normal Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2020-11-13 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04616586
The ClinicalTrials.gov registry entry for NCT04616586 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 555 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Recordati Group, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Siltuximab is the first listed.
NCT04616586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04616586 about?
NCT04616586 is a clinical study titled "SILtuximab in Viral ARds (SILVAR) Study". This study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with acute respiratory distr...
What is the current status of trial NCT04616586?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 555 participants. The study started on 2020-11-13. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT04616586?
The interventions under investigation include: Siltuximab (DRUG), Normal Saline (OTHER).
Who is sponsoring clinical trial NCT04616586?
This trial is sponsored by Recordati Group, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.